Perkin Elmer completes acquisition of Oxford Immunotec

PerkinElmer has completed its acquisition of Oxford Immunotec after previously announcing its intention in January this year. 

Prahlad Singh, PerkinElmer president and chief executive officer, said: “Oxford Immunotec’s global role in fighting tuberculosis, particularly its trademark product, the T-SPOT.TB test, and the operations it has built are remarkable. We recognise the distinct clinical and logistical advantages of the test and see a great opportunity to leverage our automation capabilities and commercial channel access to bring tuberculosis testing to more customers around the world.”

Headquartered in Abingdon, UK, Oxford Immunotec is recognised as a global leader of proprietary test kits for latent tuberculosis. Its Interferon Gamma Release Assay (IGRA) identifies individuals who are infected with tuberculosis.